Samik Pharm Co

Samik Pharm Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Samik Pharm Co (014950.KQ) as of Oct 30, 2026 is -101.62. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 155.01 — a change of -165.55% (lower).

EV/FCF

-101.62

YoY

-165.55%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Samik Pharm Co is 2025 -101.62 . EV/FCF (Enterprise Value to Free Cash Flow) of Samik Pharm Co was 2024 155.01 . It decreases by -165.55% lower compared to the previous year.

The Samik Pharm Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2023
155.01 KRW
Jan 1, 2025
-101.62 KRW
The Samik Pharm Co EV/FCF history
YEAREV/FCFYoY
-101.62-165.55%
155.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Samik Pharm Co Stock analysis

What does Samik Pharm Co do? Samik Pharm Co Ltd manufactures and sells pharmaceutical products including Cesar Plus tablets for circulatory system treatments, Eravix tablets, Griffin tablets for diabetes, Gluemser tablets, Samik Pharmotidine tablets for digestive issues, Rebacode tablets, Tamitrasemi tablets, and Seklfen tablets as antipyretic anti-inflammatory drugs. The company also produces medications for treating acute vaginal candidiasis, motion sickness in children, and alopecia. Products are sold domestically in Korea and internationally. The firm's revenue comes from the sale of these branded pharmaceutical products to healthcare providers and pharmacies in both domestic and international markets. Key product lines include cardiovascular, diabetes, digestive health, and anti-inflammatory treatments, alongside specialized medications for specific conditions like vaginal candidiasis and motion sickness. The company targets healthcare professionals and consumers seeking treatment for these medical conditions through its domestic and global distribution channels. Samik Pharm Co Ltd's business model relies on the manufacturing and global distribution of its branded pharmaceutical products. The company focuses on delivering targeted treatments for circulatory, diabetes, digestive, and inflammatory conditions, as well as specialized solutions for vaginal candidiasis, motion sickness, and alopecia. Its products are marketed to healthcare providers and end consumers across Korea and overseas markets, generating revenue through direct sales and distribution agreements. Samik Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Samik Pharm Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Samik Pharm Co is -101.62 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Samik Pharm Co changed from 155.01 to -101.62, representing a -165.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Samik Pharm Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Samik Pharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Samik Pharm Co

All Key Metrics — Samik Pharm Co